Megan McGarvey, MD
Endocrinology, Diabetes & Metabolism · la Jolla, CANPI 1255563565
Payments from drug & device makers
Across 98 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$281
- AstraZeneca$218
- Abbott$216
- Novo Nordisk$172
- Sanofi-aventis U.S. LLC$162
- Amgen$155
- plus $575 from 14 others
What the payments were for
- Food & beverage$1,779100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $281 |
| AstraZeneca(2 entities) | 10 | $218 |
| Abbott | 13 | $216 |
| Novo Nordisk | 12 | $172 |
| Sanofi-aventis U.S. LLC | 7 | $162 |
| Amgen(2 entities) | 9 | $155 |
| BETA Bionics, Inc. | 7 | $103 |
| Lilly USA, LLC | 6 | $87 |
| Insulet Corporation | 4 | $81 |
| Medtronic(2 entities) | 3 | $71 |
| BD | 2 | $54 |
| Dexcom, Inc. | 2 | $28 |
| Ascensia Diabetes Care US Inc. | 2 | $26 |
| Merck | 2 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Viiv Healthcare Company | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Mannkind Corporation | 1 | $11 |
How this compares
$1,779 in reported general payments places this provider in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $148,330 |
| JardianceEmpagliflozin | 60 | $67,574 |
| MounjaroTirzepatide | 47 | $55,460 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $45,345 |
| JanuviaSitagliptin Phosphate | 30 | $28,664 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $17,006 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $13,740 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $9,764 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $8,065 |
| SynthroidLevothyroxine Sodium | 71 | $7,177 |
| Levothyroxine Sodium | 168 | $4,556 |
| HumalogInsulin Lispro | 15 | $3,765 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,705 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $2,536 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 18 | $2,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $172 | $148,33094 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $281 | $112,91988 claims |
| Lilly USA, LLCMounjaro, Humalog | $87 | $59,22562 claims |
| MerckJanuvia, Janumet Xr | $25 | $45,67041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in la Jolla
- Athena Philis-Tsimikasla Jolla$6M
- Daniel Einhornla Jolla$578K
- James McCallumla Jolla$399K
- Renil Rodriguez Martinezla Jolla$361K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.